Fat metabolism, the fibrinogen/fibrinolytic system and blood flow: new potentials for the pharmacological treatment of coronary heart disease

Pharmacology
L Pickart

Abstract

Recent studies have emphasized the role of blood fibrinogen as a major determinant of blood and plasma viscosity in the microcirculation, of red cell and platelet aggregation, and in the growth of atheromatous lesions. Blood fibrinogen levels are increased and the endogenous fibrinolytic activity decreased by conditions or factors which raise plasma free fatty acid levels. Conversely, a wide variety of hypolipidemic agents lower fibrinogen levels and increase endogenous fibrinolytic activity apparently by reducing hepatic synthesis of fibrinogen and antifibrinolysins. These observations may open a new avenue for the pharmacological development of agents capable of improving the patterns of blood flow in patients with circulatory impairments.

Citations

Nov 1, 1990·Trends in Pharmacological Sciences·N S Cook, D Ubben
Jul 1, 1997·Thrombosis Research·D A Handley, T E Hughes
Oct 30, 1998·Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery·V Martin-ParederoC M Richard
Jun 1, 1990·Journal of Internal Medicine·E Ernst
Oct 12, 2000·The American Journal of Cardiology·S D FisherUNKNOWN THROMBO Investigators
Jan 1, 1987·The Journal of Pharmacy and Pharmacology·P MoreauJ P Tillement
Mar 1, 1991·Circulation·P M Ridker, C H Hennekens
Mar 8, 2002·American Journal of Physiology. Endocrinology and Metabolism·Prabhakaran BalagopalNelly Mauras
Jan 1, 1996·Platelets·D P Mikhailidis, E S Ganotakis
Mar 1, 1995·Medical Hypotheses·M F McCarty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.